GlassScriptPhysician profile
Susan Duong
NPI 1346415114
$2,089.11
in general payments reported to CMS, 2019-2025
14 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $313 · 2021: $458 · 2022: $331 · 2023: $284 · 2024: $209 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $669.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $825.18 | 2019-2023 | Xarelto |
| Pfizer INC. | $455.81 | 2019-2024 | |
| Abbvie INC. | $293.77 | 2022-2025 | Avycaz, Teflaro, Dalvance |
| E.R. Squibb & Sons, L.L.C. | $267.52 | 2019-2025 | Eliquis, Camzyos |
| Gilead Sciences, INC. | $50.23 | 2023 | Veklury |
| Portola Pharmaceuticals, LLC | $40.09 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.38 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $24.09 | 2025 | Ultomiris |
| Merck Sharp & Dohme LLC | $20.48 | 2022 | |
| Chiesi USA, INC. | $18.23 | 2024 | Cleviprex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.21 | 2024 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.11 | 2022 | |
| Amgen INC. | $17.93 | 2024 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $13.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Duong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.